ArticleScientific reports2026
Targeting the NLRP3 inflammasome alleviates the comorbidity of chronic pain and depression via enhancing the autophagy.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Targeting Pain and Depression in Alzheimer's Disease: Translational Insights and Emerging Treatments.Pharmaceuticals (Basel, Switzerland) · 2026Review
- SIRT6 activation relieves neuropathic pain by restoring Nrf2 signaling and inhibiting NLRP3 inflammasome.Frontiers in physiology · 2026Article
- Electroacupuncture attenuates neuroinflammation by regulating the NLRP3 inflammasome pathway: an animal study.American journal of translational research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The comorbidity of chronic pain and depression exhibits the bidirectional relationship and forms a vicious cycle in disease development, diagnosis and therapy. NLRP3 inflammasome-mediated neuroinflammation is a crucial factor for the pathogenesis of pain and depression. The underlying mechanisms of NLRP3 in the comorbidity of chronic pain and depression is unclear. In this study the spared nerve injury (SNI) mouse model was constructed, NLRP3 level was pharmacologically (MCC950) and genetically (Nlrp3−/−) regulated. As a result, SNI surgery induced pain hypersensitivity, depression-like, motor impairment and cognitive dysfunction on mice. NLRP3 inflammasome was activated in the anterior cingulate cortex (ACC) of SNI mice. MCC950 administration and Nlrp3−/− increased the PWT values, prolonged the PWL times, increased the percentages of sucrose preference, shortened the immobility times, prolonged the fall latency time, increased the central and total distances, increased the cognitive index on SNI mice, additionally decreased the neuronal dysfunction and neuroinflammation, suppressed NLRP3 inflammasome activation and enhanced autophagy in ACC of SNI model mice and in the primary astrocytic cells. Thus, targeting the NLRP3 inflammasome improves chronic pain and depression via improving autophagy, neuronal dysfunction and neuroinflammation in ACC. This study provides the therapeutic targets for the comorbidity of chronic pain and depression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.